This article is mentioned in:

Introduction

Lomatogonium rotatum Fries ex Nym., which is referred to as ‘Habirigan-Digeda’ in Mongolian, is the whole plant of a Gentian family herb with a height of 15–40 cm. L. rotatum is contained within the Mongolian volumes of Chinese Materia Medica. As an annual herb growing on hillsides, grasslands and near ditches, L. rotatum is preferentially distributed in the mountain areas of Inner Mongolia in China. L. rotatum contains flavonoids including cynaroside and orientin (1), which previous studies have shown to be useful in the treatment of dyspepsia, gall bladder swelling, jaundice and inflammation of the liver and gallbladder (2,3). Previous studies evaluating long-term treatment with L. rotatum have demonstrated that it may lower blood lipid levels and prevent obesity (1,4); however its exact mechanism of action remains to be fully elucidated. Daily foodstuff contains some natural fructose and in recent years foods with considerable refined fructose content have become fairly popular. This is a worrying trend as a high intake of foods rich in fructose is associated with obesity and metabolic problems (5).

The lipogenic capacity exhibited by liver and adipose tissue is controlled by fatty acid synthase (FAS), and it has previously been demonstrated that FAS gene expression is vital for the conversion of fructose into lipids (6). At present, individuals often suffer from hyperlipidemia due to changes in the metabolism of lipids, and hyperlipidemia contributes to arteriosclerosis and coronary heart disease (CHD). In addition, it has been reported that high levels of triglyceride (TG) may increase the risk of CHD (7).

Previous studies have determined the effects of flavonoids extracted from L. rotatum, particularly decussatin, which has been shown to inhibit the growth of HEP-G2 hepatoma cells, resulting in reduced blood glucose levels and a decrease in depression, leukemia and tuberculosis (8,9). However, studies regarding the hypolipidemic effects of the following flavonoids: 1-hydroxy-3,5,8-trimethoxyxanthone, methyl swertiamarin and 6,8-dihydroxy-1,2-dimethoxyxanthone are rare (10–12).

Previous studies have demonstrated that L. rotatum is able to decrease blood glucose; therefore, L. rotatum may potentially be useful as a prophylactic treatment for atherosclerosis (13). In addition, following the long-term consumption of high-fructose foods, adenosine monophosphate-activated protein kinase (AMPK) in L. rotatum may continuously suppress hyperlipidemia, hyperleptinemia and FAS (14). Therefore, in the present study the hypolipidemic and obesity-inhibiting effects of four flavonoids isolated from L. rotatum (Fig. 1) were investigated in Wistar rats.

Figure 1. Chemical structures of four flavonoids extracted from Lomatogonium rotatum. (A) l-hydroxy-3,7,8-trimethoxyxanthone (decussatin); (B) 1-hydroxy-3,5,8-trimethoxyxanthone; (C) methyl swertiamarin; and (D) 6,8-dihydroxy-1,2-dimethoxyxanthone.

Materials and methods

Materials

Enzyme assay total cholesterol (TC; #4220), triglyceride (TG; #4240), polyethylene sulfate precipitation method low-density lipoprotein-cholesterol (LDL-C; #4210) and phosphotungstic acid-magnesium precipitation method high-density lipoprotein-cholesterol (HDL-C; #4200) kits were purchased from Biosino Bio-Technology and Science, Inc. (Beijing, China). Flavonoids A-D were yellow needle-like crystals with the following molecular weights: A, 302 g/mol; B, 302 g/mol; C, 288 g/mol and D, 288 g/mol. The four flavonoids were extracted and synthesized at the Inner Mongolia Medical University (Hohhot, China) (15), and uniformly mixed into the basic feeds of the experimental rats. Anti-FAS (MHCD9528) was purchased from Thermo Fisher Scientific, Inc. (Carlsbad, CA, USA), and anti-phospho AMPK (AA393), anti-AMPK (AA393-1; Beyotime Institute of Biotechnology, Shanghai, China), and horseradish peroxidase-conjugated anti-mouse (NCAM-1/CD56; R&D Systems, Inc., Minneapolis, MN, USA) and anti-rabbit (ab191866) antibodies were purchased from Abcam (Cambridge, UK).

Animals and treatment

The present study complied with all protocols and policies outlined by the Animal Care and Use Committee of Inner Mongolia Medical University. The present study complied with all protocols and policies outlined by the Animal Care and Use Committee of Inner Mongolia Medical University (Huhhot, China). A total of 60 six-week-old male Wistar rats (weight, 150–200 g), were provided by the Experimental Animal Center of Inner Mongolia Medical University, and were housed at the Inner Mongolia Medical University in stainless steel wire-bottomed cages. The rats were acclimated to the laboratory conditions (19–23°C, 60% humidity and 12-h light/dark cycle) for at least 1 week prior to the initiation of the present study, during which the rats received ad libitum access to water and Purina® rat food. Following one week of acclimation, the rats were divided into the following groups, and subsequently weighed every week for 12 weeks (16–18): Control group, basic diet (Purina® rat food); Model group, high-fructose diet (40% Purina® rat food + 60% fructose); Group A, high-fructose diet + 20 mg/kg flavonoid A; Group B, high-fructose diet + 20 mg/kg flavonoid B; Group C, high-fructose diet + 20 mg/kg flavonoid C; Group D, high-fructose diet + 20 mg/kg flavonoid D. Blood samples were collected from the femoral arteries of the rats, and the serum was separated in order to detect the levels of TC, TG, HDL-C and LDL-C. Hepatic, kidney and epididymal adipose tissue samples were harvested, weighed and stored at −70°C.

Determination of TG

Serum levels of TG were analyzed using the glycerol-3-phosphate oxidase/phenol and aminophenazone method (Biosino Bio-Technology and Science Inc.) (19,20). TG was enzymatically hydrolyzed to glycerol and free fatty acids using specific lipases, which were subsequently oxidized into H2O2 using glycerol kinase and glycerol phosphatase. H2O2 was then converted into colored quinonimine via a peroxidase-catalyzed reaction with 4-aminoantipyrine and phenol. The levels of TG in the serum samples were determined at 520 nm and expressed as mg/100 ml (21).

Determination of TC

Serum levels of TC were measured using the cholesterol oxidase/phenol and aminophenazone (CHOD-PAP) method (Biosino Bio-Technology and Science Inc.). Using detergents, cholesterol and its esters were released from lipoproteins prior to hydrolyzation of the esters using cholesterol esterase, which were subsequently enzymatically oxidized into H2O2. H2O2 was then converted into colored quinonimine via a peroxidase-catalyzed reaction with 4-aminoantipyrine and phenol. The levels of TC in the serum samples were determined at 520 nm and expressed as mg/100 ml (21).

Determination of HDL-C

LDL was precipitated by phosphotungstic acid and magnesium ions, which were subsequently removed by centrifugation in order to suspend the HDL in the supernatant. HDL-C was then measured using the CHOD-PAP method (Biosino Bio-Technology And Science Inc.). The levels of HDL-C in the serum samples were expressed as mg/100 ml.

Determination of LDL-C

LDL was precipitated by heparin at its isoelectric point (pH 5.12). HDL remained in the supernatant following centrifugation and the levels of LDL-C were subsequently determined by enzymatic methods: LDL-C level = TC level - level of cholesterol in the supernatant. The content of LDL-C in the serum samples was expressed as mg/100 ml.

Determination of blood glucose

Glucose levels were measured following 12 weeks of feeding. The tails of the rats were stored in a water bath at 45°C prior to the collection of blood samples from 1 mm of the tail end. Glucose detection was conducted according to the ortho-tolidine method (22).

Determination of alanine aminotransferase (ALT), aspartate aminotransferase (AST), non-esterified fatty acid (NEFA), insulin and leptin levels

Serum ALT, AST and NEFA levels were determined according to the manufacturer's instructions (Biosino Bio-Technology And Science Inc.). The insulin concentrations of the serum samples were determined using a Rat Insulin ELISA kit (Mercodia, Uppsala, Sweden), and the tests were 100% cross-reactive with human and rat insulin. During incubation, insulin in the sample reacted with peroxidase-conjugated anti-insulin and bound to the microtitration well. The unbound enzyme-labeled antibodies were subsequently removed by a facile washing step, and the bound conjugate was detected following the addition of 3,3′,5,5′-tetra-methylbenzidine. Acids were added to terminate the reaction and the absorbance was measured at 450 nm. Serum leptin levels were determined using a Rat Leptin TiterZyme Enzyme Immunometric Assay kit (Applied Biosystems; Thermo Fisher Scientific, Inc., Foster City, CA, USA), under normal conditions. Leptin was immobilized by a polyclonal antibody on a microtiter plate and, after a short incubation, the excessive sample was rinsed, and leptin polyclonal antibody labeled with horseradish peroxidase was added. Subsequently, the excessive antibody was rinsed and the substrate was added prior to incubation for 30 min. The absorbance of the resultant colored solutions was detected at 450 nm, which was directly proportional to the concentrations of leptin in the respective samples (23).

Determination of total lipids, TG and TC in the liver. To detect the levels of hepatic total lipids, TG and TC, the rat livers were homogenized using a mixed chloroform/methanol/water (8:4:3) solution (LabGEN 7 Homogenizer; Cole-Parmer, Vernon Hills, IL, USA). The resultant mixture was shaken at 37°C for 1 h and centrifuged at 2,000 × g for 10 min. Subsequently, the bottom layer was collected and resuspended in order to analyze the hepatic lipids. The levels of TG, TC and total lipids were measured according to the enzymatic protocol outlined by Biosino Bio-Technology And Science Inc. (24).

Reverse transcription polymerase chain reaction (RT-PCR) analysis

Total RNA was isolated from liver tissue samples using ISOGEN® reagent (Nippon Gene Co., Ltd., Toyama, Japan). Briefly, cDNA was prepared from 5 µg total RNA, oligo (dT)18 primer and Moloney murine leukemia virus reverse transcriptase (Promega Biotech Co., Ltd., Beijing, China) by incubation at 40°C for 90 min. The total PCR volume was 50 µl containing dNTPs, 1 µl reaction buffer, 1 µM primers (FAS, forward 5′-CCACTAGAAGCGTCTGCTGATCTG-3′; reverse, 5′-TGCTATGTCCTACATATCGAGGACGC-3′), 2 µl reverse transcriptase and 50 Uml-1 Taq DNA polymerase. A total of 5 µl PCR products were subsequently separated by 2% agarose gel electrophoresis and were visualized via staining with ethidium bromide.

Western blotting

Each liver sample was homogenized in lysis buffer containing 50 mM Tris-HCl buffer, 50 mM NaF, 5 mM sodium pyrophosphate, 0.25 M sucrose, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride and 0.5% sodium dodecyl sulfate (pH 7.5). The tissue lysates were then centrifuged in order to remove insoluble substances and the respective protein contents were measured using a Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The proteins were subsequently separated by 10% SDS-PAGE (Bio-Rad Laboratories, Inc.) and electro-transferred onto a polyvinylidene difluoride membrane, which was then pre-incubated overnight at 4°C in phosphate-buffered saline containing 0.01% Tween-20, 1% bovine serum albumin (Nanjing SenBeiJia Biological Technology Co., Ltd., Nanjing, China) and 0.2% NaN3. Following this, the proteins were successively incubated with various primary antibodies and secondary anti-rabbit/goat/mouse IgG conjugated to horseradish peroxidase. The immunoreactive bands were visualized using enhanced chemiluminescent reagents.

Statistical analysis

All data were analyzed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) and expressed as the mean ± standard deviation. The mean values were derived from three independent experiments. Two groups were compared by Students t-test (Mann-Whitney test was used in the case of heterogeneity of variance), and multiple groups were compared by one-way analysis of variance with Student-Newman-Keuls post-hoc analysis. P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of flavonoids extracted from L. rotatum on body weight and diet intake

The metabolism of Wistar rats may be affected by 60% fructose intake, which is associated with as glucose tolerance, high serum TG levels and increased insulin resistance; therefore, rats in the model group were fed foodstuff containing 60% fructose (25,26). The present study aimed to compare the effects of various flavonoids from L. rotatum on 6-week-old Wistar rats with high fructose-induced hyperlipidemia. Experimental rats, weighing ~150 g each, were divided into six groups (n=10), and fed various diets for 12 weeks. The rats were weighed weekly and the observed weight changes are outlined in Fig. 2. The body weight of the rats in the model group was significantly increased from the 3rd week, whereas the weight of the rats in the control and flavonoid groups increased steadily without significant differences. The flavonoid D group exhibited the lowest mean weight. The food intake data for all of the experimental groups are presented in Fig. 3. Food intake volume and body weight were linearly correlated in all groups except the model group.

Figure 2. Changes in the body weight of rats fed 60% fructose and 5 mg/kg flavonoids for 12 weeks. Data are presented as the mean ± standard deviation. ◆Control group; ■model group; ▲Group A; *Group B; ×Group C; ●Group D.

Figure 3. Daily food intake data of the various groups. ◆Control, 26.5±1.2 g; ■model, 23.9±2.9 g; ▲flavonoid A, 27.7±1.7 g; *flavonoid B, 26.2±2.2 g; ×flavonoid C: 25.1±1.2 g; and ●flavonoid D groups: 26.8±1.4 g.

Effects of flavonoids extracted from L. rotatum on liver, kidney and adipose tissue weight

The weight of the rat hepatic, renal and epididymal adipose tissues are outlined in Table I. L. rotatum flavonoids did not influence the liver weight of the rats; whereas the epididymal adipose tissues of the rats fed various flavonoids weighed less, as compared with those only fed fructose. In addition, the weight of the kidney tissues harvested from rats fed L. rotatum flavonoids were also lower, as compared with the model group, with the exception of the flavonoid B group.

Table I. Effects of flavonoids extracted from Lomatogonium rotatum on the weight of liver, kidney and adipose tissues.

Table I.

Effects of flavonoids extracted from Lomatogonium rotatum on the weight of liver, kidney and adipose tissues.

	Liver		Epididymal adipose tissue		Kidney
Group	Weight (g)	Relative weight	Weight (g)	Relative weight	Weight (g)	Relative weight
Control	15.8±2.2	3.6±0.3	7.2±0.3	1.5±0.2a	3.3±0.2	0.77±0.2
Model	16.5±0.9	3.8±0.4	6.8±0.5	1.7±0.4a	3.1±0.5	0.82±0.3a
A	14.9±2.4	4.1±0.5	5.0±1.1	1.3±0.4b	2.7±0.3	0.74±0.4b
B	13.8±1.5	4.3±0.3b	5.2±0.4	1.3±0.5b	2.5±0.1b	0.77±0.3
C	14.7±1.5	4.1±0.2	4.9±1.0*	1.4±0.2b	2.5±0.4b	0.71±0.1b
D	14.2±2.3	4.2±0.4	4.7±0.6*	1.4±0.3b	2.6±0.2	0.72±0.2b

a P<0.05 vs. the control group

b P<0.05 vs. the model group. A-D, flavonoid A-D groups.

Effects of flavonoids extracted from L. rotatum on lipid metabolism

It has been revealed that rats fed a high-fructose diet may suffer from increased insulin resistance, hyperinsulinemia, hypertriglyceridemia and hypertension. To verify the effects of L. rotatum flavonoids on lipid metabolism, serum and liver tissue samples from Wistar rats were analyzed. In the present study, a high-fructose diet significantly elevated the levels of serum insulin, leptin and NEFA (Table II). Following a 12-week administration of L. rotatum flavonoids, the levels of fasting blood glucose, feeding blood glucose and leptin in the serum had decreased to normal. In addition, the rats in flavonoid groups A and D exhibited reduced levels of serum cholesterol, insulin, leptin and NEFA (Table II). Rats in flavonoid B group demonstrated improved liver function; however, function was not completely recovered. In addition, in the flavonoid C group feeding blood glucose levels did not return to normal.

Table II. Relative clinical and biochemical indices following a 12-week administration.

Table II.

Relative clinical and biochemical indices following a 12-week administration.

Group	ALT (U·l−1)	AST (U·l−1)	NEFA (mmol·l−1)	Fasting blood glucose (mg·dl−1)	Feeding blood glucose (mg·dl−1)	Insulin (pmol·l−1)	Leptin (ngm·l−1)
Control	31.5±0.26	105.3±1.41	0.17±0.02	63.2±4.7	95.6±10.1	142.6±36.5	20.04±1.2
Model	26.3±0.34a	95.4±0.97a	0.33±0.01a	73.5±3.6a	122.6±20.3a	188.7±42.2a	25.4±2.2a
A	23.7±0.65b	99.8±0.45b	0.23±0.05b	59.6±3.5b	92.6±16.8b	109.6±33.1b	19.6±2.5b
B	25.2±0.42	92.4±0.87	0.26±0.03	60.1±4.5b	95.8±17.6b	121.4±35.6b	22.3±0.8b
C	24.1±0.24b	99.3±0.64b	0.24±0.01b	64.5±1.2b	101.3±15.4	133.4±45.6b	20.4±1.5b
D	22.8±0.76b	91.5±0.75	0.24±0.05b	63.3±6.0b	97.8±11.9b	136.8±26.1b	21.8±3.3b

a P<0.05 vs the control group

b P<0.05 vs the model group. A-D, flavonoid A-D groups. ALT, alanine transaminase; AST, aspartate transaminase; NEFA, non-esterified fatty acids.

To determine the effects of L. rotatum flavonoids on the homeostasis of liver fat, hepatic fat accumulation was investigated in rats. The resultant liver fat content (Fig. 4) and TG and cholesterol levels (Fig. 5) indicate that fructose-rich foods may significantly increase fat accumulation in the liver. The fat content, and serum TG and cholesterol levels were all significantly lowered after 12-week administration of L. rotatum flavonoids, as compared with rats fed only a high-fructose diet. Thus suggesting that L. rotatum flavonoids successfully reduced hepatic fat content, and blood TG and cholesterol levels, as well as increasing serum HDL-C levels. As outlined in Fig.5, flavonoid A demonstrated good therapeutic action in reducing total cholesterol; however, the LDL-C levels were not significantly altered. Furthermore, following flavonoid C administration the resultant serum lipid parameters demonstrated good pharmacological activity, with a significant reduction in LDL-C levels (P<0.05), and flavonoids B and D functioned similarly.

Figure 4. Effects of flavonoids extracted from Lomatogonium rotatum on hepatic fat accumulation in rats fed a fructose-rich diet. Data are presented as the mean ± standard deviation (n=10). *P<0.05 vs. the model group. A-D, flavonoid A-D groups.

Figure 5. Effects of flavonoids extracted from Lomatogonium rotatum on blood lipid indices. (A) TC (white) and LDL-C (black); (B) TG (white) and HDL-C (black). ∆P<0.05 vs. the control group; *P<0.05 vs. the model group. Data are presented as the mean ± standard deviation (n=10). TC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol. A-D, flavonoid A-D groups.

Effects of flavonoids extracted from L. rotatum on the expression levels of FAS and pAMPK

Previous studies have demonstrated that fructose-rich foods may elevate TG levels in the liver and blood, and a high fructose intake may result in hypertriglyceridemia in rats. Fructose-induced hypertriglyceridemia is considered to originate from the excessive secretion of TG in the liver (27), with the enhanced expression of several enzymes, including FAS, associated with the promotion of hepatic TG secretion. After detecting the FAS levels in rat liver samples, we hypothesize that the hypolipidemic effects of L. rotatum flavonoids are realized by inhibiting the expression of FAS. We also estimate that FAS activity is controlled by enzyme content rather than changes in chemical bond or enzymatic structure. RNA and protein samples were extracted from the liver of rats fed various L. rotatum flavonoids, in order to conduct RT-PCR and western blotting. In the present study, the administration of a high-fructose diet significantly increased FAS mRNA and protein expression levels (Figs. 6 and 7) in rats, as compared with the other groups. FAS mRNA expression levels were significantly decreased (P<0.01) in the rats fed L. rotatum flavonoids, and the four flavonoids appeared to function identically. In addition, the protein levels of FAS were successfully controlled in all of the flavonoid groups; however, the effects of flavonoid D were most evident (P<0.01). Another important indicator is the phosphorylation of AMPK in the liver of the rats. Western blot analysis demonstrated that flavonoid C significantly decreased the threonine-172 phosphorylation of AMPK in the liver lysates (P<0.01; Fig. 7).

Figure 6. FAS mRNA expression levels, as detected by reverse transcription polymerase chain reaction. (A) Agarose gel electrophoresis analysis and (B) relative FAS mRNA expression levels. ∆P<0.05 vs. the control; **P<0.01 vs. the model group. FAS, fatty acid synthase; A-D, flavonoid A-D groups.

Figure 7. Protein expression levels of FAS, and pThr172-AMPK in the liver. ∆P<0.05 vs. the control group; **P<0.01. Black, FAS; grey, pThr172-AMPK. Hsp90, heat shock protein 90; FAS, fatty acid synthase; pThr172-AMPK, threonine-172 phosphorylated adenosine monophosphate-activated protein kinase; A-D, flavonoid A-D groups.

Discussion

Hypercholesterolemia and hypertriglyceridemia are considered important factors associated with the incidence of atherosclerosis and CHD. In the present study, rats fed a high-fructose diet demonstrated hyperlipidemia, increased body weight, adipose tissue and blood insulin levels, and decreased glucose tolerance. A previous study demonstrated that Wistar rats experienced a significant increase in lipid levels after being fed a high-fructose diet for two weeks, and the effect became more apparent after 10 weeks (28). Flavonoid A, which is the most frequently assessed of the four flavonoids, is capable of preventing atherosclerosis by decreasing blood pressure. Flavonoids A-D are obtained from the same plant and have similar structures; therefore, their common effects should be considered (9,29). In the present study, the levels of TC, LDL-C and TG were significantly increased, and the HDL-C levels were significantly decreased in the model group, as compared with the control group, suggesting that the model was successfully established. In the flavonoid C group, the four serum lipid parameters were improved following treatment, and LDL-C was the only parameter to not demonstrate a significant change in the flavonoid D group. Furthermore, TC, TG and HDL-C levels were significantly improved in the flavonoid A group, and TC and TG were significantly decreased in the flavonoid B group.

Following a 12-week administration of L. rotatum flavonoids, serum levels of fasting blood glucose and feeding blood glucose were significantly decreased. The rats in the flavonoid A and D groups demonstrated reduced levels of serum insulin; however, feeding blood glucose levels did not return to normal in the flavonoid C group. These results suggested that flavonoid C may produce insulin resistance in rats, which should be the focus of more detailed studies in the future (30). Leptin is encoded by the Ob gene, and the amount of adipose tissue and insulin secretion can increase the levels of serum leptin. Therefore, the leptin levels of rats fed a high-fructose diet should be higher, as compared with those in the control group. The present study demonstrated that high-fructose foods may lead to excessive insulin secretion, thereby stimulating the production of leptin (29,31). All L. rotatum flavonoids were able to downregulate leptin and, owing to their potential hypolipidemic effects, further studies investigating the flavonoids of various Mongolian medicines are recommended in the future.

Epidemiological studies have demonstrated that flavonoid intake is inversely related to CHD. FAS is involved in energy metabolism, and is associated with various human diseases, including obesity, cardiovascular disease and cancer. Previous studies have reported that epigallocatechin 3-gallate (EGCG) in flavonoids may inhibit FAS in the liver of broiler chickens (32,33). In the present study, the majority of the flavonoids successfully reduced the relative weight of epididymal adipose tissue. Therefore, the authors of the present study infer that flavonoids A, B and D have a similar effect to EGCG in inhibiting the activity of FAS. A previous in-depth study investigated the molecular dynamic mechanisms of L. rotatum flavonoids on the expression of FAS (6), and such studies should be continued in the future. All L. rotatum flavonoids may inhibit the expression of FAS in the liver by stimulating AMPK activity in hepatocyte cells via the liver kinase B1 pathway (34). Furthermore, the majority of flavonoids decreased the threonine-172 phosphorylation of AMPK in the liver lysate, which suggested that flavonoids stimulate AMPK activity, thereby reducing fatty acid synthesis in the liver and fat accumulation (35). Furthermore, the activities of acetyl-CoA carboxylase and FAS may be inhibited; however, the mechanisms of FAS inhibition and anti-obesity remain unclear, and future studies are required.

In conclusion, the present study demonstrated that certain flavonoids extracted from L. rotatum may mitigate hypercholesterolemia and hypertriglyceridemia induced by the intake of high-fructose foods, as well as improve the metabolism of lipids and leptin in rats with insulin resistance. The four flavonoids that were investigated decreased the levels of TG, total cholesterol, leptin and insulin within a certain range, and improved insulin resistance, liver function, and HDL-C levels. The present study also demonstrated that flavonoid C exhibited the best overall effects and inhibited FAS in the liver tissue of rats. However, the metabolic mechanisms investigated in the present study are not identical between humans and experimental rats, therefore it remains unclear whether the flavonoids may also prevent fat accumulation in the human liver. As such, the pharmacological effects of flavonoids should be further investigated in humans. These findings may contribute to the treatment of fatty liver and obesity-associated diseases in humans.

Acknowledgements

The present study was financially supported by the Nature Science Foundation of Inner Mongolia Autonomous Region (grant no. 2013MS1224), the Scientific Project of the Affiliated Hospital of Inner Mongolia Medical University (grant no. NYFY2010YB006), the Inner Mongolia Medical University Youth Innovation Fund (grant no. NY2010QN002), and the Key Scientific Fund of the Affiliated Hospital of Inner Mongolia Medical University (grant no. NYFYZD20130158).

References